Moreover, results from the first clinical trial of sulforaphane-rich extracts in men with prostate cancer revealed a positive effect in decreasing PSA levels, in spite of having not achieved its primary endpoint [153,154]. This evidence concerns the gene KLK3 and prostate carcinoma.